Results 151 to 160 of about 15,069 (219)
A real‐world data‐driven approach to optimizing enoxaparin dosing in burn patients
British Journal of Clinical Pharmacology, EarlyView.Aim Enoxaparin dosing in burn patients is challenging due to physiological changes affecting absorption, distribution and clearance. The objectives of this study are to develop a population pharmacokinetic (PK) model for enoxaparin in burn patients, evaluate target attainment with current equation‐based (EQ) dosing and propose an optimized dosing ...
Babajide Shenkoya +3 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Tranexamic acid (TXA) stabilizes clot formation by inhibiting fibrin degradation and improves postoperative outcomes. However, rare adverse events (e.g., thrombosis, seizures) warrant dose–risk evaluation. This study examines how perioperative blood loss and transfusion practices affect TXA concentrations during paediatric scoliosis surgery ...
Paula Alexandra Sá +4 more
wiley +1 more source
Dupilumab‐Related Adverse Events and Intolerance in Aspirin‐Exacerbated Respiratory Disease Patients
International Forum of Allergy &Rhinology, EarlyView.
Lancelot P. Herpin +8 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale +5 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Levothyroxine (LT4) is the standard treatment for hypothyroidism and the most widely prescribed medication worldwide. Although generally safe, regulatory reports list potential cardiac, neuropsychiatric and musculoskeletal adverse events (AEs). Clarifying their clinical relevance is essential.
Bala Swetha Baskaran +2 more
wiley +1 more source
Possible therapeutic repositioning of valproic acid: From epileptic seizures to acute kidney injury
British Journal of Clinical Pharmacology, EarlyView.Valproic acid, an anticonvulsant, may be repositioned to prevent acute kidney injury due to ischemia followed by reperfusion. It preserves renal functions, electrolyte homeostasis and active sodium transport in kidney tubules, and blocks the onset of hypertension.
Danilo Alves‐Bezerra +8 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse +3 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Aims This work assessed the pharmacokinetics (PK), safety and tolerability of glasmacinal (EP395, an oral anti‐inflammatory macrolide with negligible antimicrobial activity in development for COPD treatment) in two healthy participant trials: ‘first‐in‐human’ (FIH) and ‘drug–drug‐interaction’ (DDI).
Dave Singh +5 more
wiley +1 more source